{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:46:24Z","timestamp":1792449984062,"version":"4.5.0"},"reference-count":42,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA014089"],"award-info":[{"award-number":["P30CA014089"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA268383"],"award-info":[{"award-number":["R01CA268383"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA023074"],"award-info":[{"award-number":["P30CA023074"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009856","name":"L. K. Whittier Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Acute myeloid leukemia (AML) remains defined by therapeutic resistance, adverse genetic heterogeneity, and poor long-term survival, underscoring the need for mechanistically informed regimens that exploit core stress-adaptation liabilities. Polo-like kinase 1 (PLK1) is a central regulator of replication recovery and mitotic progression, yet direct PLK1 inhibitors have been limited by tolerability and incomplete target suppression. Here, we define a clinically actionable strategy that functionally targets PLK1 by combining inhibition of the AAA+ ATPase p97\/valosin-containing protein with the hypomethylating agent decitabine (DAC). Using AML cell lines, primary patient specimens, and an orthotopic in vivo model, we show that the clinically relevant p97 inhibitor CB-5339 induces proteotoxic and replication stress, activates the unfolded protein response, and triggers apoptosis. Formal synergy analyses demonstrate that CB-5339 and DAC cooperate across molecular subtypes, including FLT3-ITD+, KMT2A-rearranged, and TP53-mutant AML, to reduce cell viability at pharmacologically relevant concentrations. Transcriptomic, biochemical, and genetic studies identify synergistic suppression of PLK1 as a central consequence of combination treatment, converting stress-dependent PLK1 reliance into a therapeutic vulnerability. Consistent with this mechanism, PLK1 knockdown phenocopies the antileukemic effects of the combination and enhances sensitivity to both agents. In vivo, CB-5339\/DAC is well tolerated, significantly prolongs survival, reduces leukemic burden, and suppresses PLK1 in bone marrow blasts. Together, these data establish p97 inhibition as a rational means to exploit replication and proteotoxic stress in AML and provide strong rationale for clinical evaluation of CB-5339 plus DAC in high-risk disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study defines a clinically actionable strategy to overcome therapeutic resistance in AML by functionally suppressing PLK1 through combined p97 inhibition and hypomethylating therapy. By exploiting convergent proteotoxic and replication stress, the regimen produces robust, well-tolerated antileukemic activity across high-risk genetic subtypes, supporting near-term clinical evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0035","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T22:03:38Z","timestamp":1780697018000},"page":"1509-1521","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["p97 Inhibition Synergistically Enhances Hypomethylating Therapy through Targeting of PLK1 in Acute Myeloid Leukemia"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8767-3969","authenticated-orcid":false,"given":"Steffan T.","family":"Nawrocki","sequence":"first","affiliation":[{"name":"1Division of Translational Medicine, Department of Medicine, University of Arizona Cancer Center, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2016-5630","authenticated-orcid":false,"given":"Ning","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southern California 2 Division of Hematology, Department of Medicine, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4109-2584","authenticated-orcid":false,"given":"Claudia M.","family":"Espitia","sequence":"additional","affiliation":[{"name":"1Division of Translational Medicine, Department of Medicine, University of Arizona Cancer Center, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3062-7450","authenticated-orcid":false,"given":"Harley","family":"Wu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southern California 3 Division of Hematology, Health Sciences Campus, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6727-0505","authenticated-orcid":false,"given":"Claudia","family":"Villa Celi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0155k7414","id-type":"ROR","asserted-by":"publisher"}],"name":"Cleveland Clinic Florida 4 Division of Hematology and Oncology, , Weston, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9040-0804","authenticated-orcid":false,"given":"Julian","family":"Olea","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southern California 3 Division of Hematology, Health Sciences Campus, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0643-4059","authenticated-orcid":false,"given":"Paniz","family":"Zarand","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southern California 3 Division of Hematology, Health Sciences Campus, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5611-2883","authenticated-orcid":false,"given":"Homa","family":"Dadrastoussi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southern California 3 Division of Hematology, Health Sciences Campus, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7660-9398","authenticated-orcid":false,"given":"Hittu","family":"Matta","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southern California 3 Division of Hematology, Health Sciences Campus, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9317-0371","authenticated-orcid":false,"given":"Sruthi","family":"Sureshkumar","sequence":"additional","affiliation":[{"name":"1Division of Translational Medicine, Department of Medicine, University of Arizona Cancer Center, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3731-7142","authenticated-orcid":false,"given":"Madison E.","family":"Gamble","sequence":"additional","affiliation":[{"name":"1Division of Translational Medicine, Department of Medicine, University of Arizona Cancer Center, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8617-6319","authenticated-orcid":false,"given":"Natalie L.","family":"Hakim","sequence":"additional","affiliation":[{"name":"1Division of Translational Medicine, Department of Medicine, University of Arizona Cancer Center, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0845-4167","authenticated-orcid":false,"given":"David","family":"Drum","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southern California 3 Division of Hematology, Health Sciences Campus, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6312-2171","authenticated-orcid":false,"given":"Jack","family":"Angeles","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southern California 3 Division of Hematology, Health Sciences Campus, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6604-5775","authenticated-orcid":false,"given":"Kaijin","family":"Wu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southern California 3 Division of Hematology, Health Sciences Campus, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0551-5161","authenticated-orcid":false,"given":"Jiang F.","family":"Zhong","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04bj28v14","id-type":"ROR","asserted-by":"publisher"}],"name":"Loma Linda University 5 Department of Basic Science, School of Medicine, , Loma Linda, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9051-0802","authenticated-orcid":false,"given":"Xuelian","family":"Chen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southern California 3 Division of Hematology, Health Sciences Campus, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3638-1740","authenticated-orcid":false,"given":"Alex","family":"Duong","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southern California 3 Division of Hematology, Health Sciences Campus, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8578-8292","authenticated-orcid":false,"given":"Jennifer S.","family":"Carew","sequence":"additional","affiliation":[{"name":"1Division of Translational Medicine, Department of Medicine, University of Arizona Cancer Center, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3638-5956","authenticated-orcid":false,"given":"Kevin R.","family":"Kelly","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southern California 3 Division of Hematology, Health Sciences Campus, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"2026062606020694500_bib1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ijc.70197","article-title":"DNA methyltransferase inhibitors in hematological malignancies and solid tumors","volume":"158","author":"Wenger","year":"2026","journal-title":"Int J Cancer"},{"key":"2026062606020694500_bib2","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2767-9764.CRC-25-0091","article-title":"A phase 1b\/2 study of TP-0903 and decitabine targeting mutant TP53 and\/or complex karyotype in patients with untreated acute myeloid leukemia \u2265age 60 years","volume":"5","author":"Eisenmann","year":"2025","journal-title":"Cancer Res Commun"},{"key":"2026062606020694500_bib3","first-page":"125","article-title":"Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia","volume":"4","author":"Saliba","year":"2021","journal-title":"Cancer Drug Resist"},{"key":"2026062606020694500_bib4","doi-asserted-by":"crossref","first-page":"100805","DOI":"10.1016\/j.drup.2022.100805","article-title":"Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia","volume":"61","author":"\u0160imoni\u010dov\u00e1","year":"2022","journal-title":"Drug Resist Updat"},{"key":"2026062606020694500_bib5","doi-asserted-by":"crossref","first-page":"e184665","DOI":"10.1172\/JCI184665","article-title":"Ubiquitin-conjugating enzyme UBE2N modulates proteostasis in immunoproteasome-positive acute myeloid leukemia","volume":"135","author":"Ishikawa","year":"2025","journal-title":"J Clin Invest"},{"key":"2026062606020694500_bib6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/blood.2024026749","article-title":"The proteostasis network is a therapeutic target in acute myeloid leukemia","volume":"147","author":"Lam","year":"2026","journal-title":"Blood"},{"key":"2026062606020694500_bib7","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.3390\/cancers17182945","article-title":"Harnessing p97\/VCP: a transformative AAA+ ATPase target for next-generation cancer therapeutics","volume":"17","author":"Carrera Espinoza","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026062606020694500_bib8","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ccell.2015.10.002","article-title":"Targeting the AAA ATPase p97 as an approach to treat cancer through disruption of protein homeostasis","volume":"28","author":"Anderson","year":"2015","journal-title":"Cancer Cell"},{"key":"2026062606020694500_bib9","doi-asserted-by":"crossref","first-page":"e2200109","DOI":"10.1002\/prca.202200109","article-title":"Valosin-containing protein (VCP\/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: a report from the Children\u2019s Oncology Group","volume":"17","author":"Hoff","year":"2023","journal-title":"Proteomics Clin Appl"},{"key":"2026062606020694500_bib10","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/s41375-025-02670-y","article-title":"5-Azacytidine and decitabine induce C &gt; G transversions in both murine and human cells","volume":"39","author":"Bertoli","year":"2025","journal-title":"Leukemia"},{"key":"2026062606020694500_bib11","doi-asserted-by":"crossref","first-page":"113098","DOI":"10.1016\/j.celrep.2023.113098","article-title":"Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment","volume":"42","author":"Yabushita","year":"2023","journal-title":"Cell Rep"},{"key":"2026062606020694500_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00412-016-0587-4","article-title":"Strategic role of the ubiquitin-dependent segregase p97 (VCP or Cdc48) in DNA replication","volume":"126","author":"Ramadan","year":"2017","journal-title":"Chromosoma"},{"key":"2026062606020694500_bib13","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/s41418-022-01000-4","article-title":"The phosphorylation and dephosphorylation switch of VCP\/p97 regulates the architecture of centrosome and spindle","volume":"29","author":"Zhu","year":"2022","journal-title":"Cell Death Differ"},{"key":"2026062606020694500_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.canlet.2020.06.020","article-title":"Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer","volume":"491","author":"Nieto-Jimenez","year":"2020","journal-title":"Cancer Lett"},{"key":"2026062606020694500_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2018.08.007","article-title":"Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer","volume":"436","author":"Wang","year":"2018","journal-title":"Cancer Lett"},{"key":"2026062606020694500_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/17460441.2023.2159942","article-title":"Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer","volume":"18","author":"Stafford","year":"2023","journal-title":"Expert Opin Drug Discov"},{"key":"2026062606020694500_bib17","doi-asserted-by":"crossref","first-page":"9402","DOI":"10.1038\/s41467-024-53535-4","article-title":"Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia","volume":"15","author":"Wegmann","year":"2024","journal-title":"Nat Commun"},{"key":"2026062606020694500_bib18","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1097\/HS9.0000000000000617","article-title":"Adjunctive volasertib in patients with acute myeloid leukemia not eligible for standard induction therapy: a randomized, phase 3 trial","volume":"5","author":"D\u00f6hner","year":"2021","journal-title":"Hemasphere"},{"key":"2026062606020694500_bib19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1158\/1078-0432.CCR-09-1385","article-title":"Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels","volume":"16","author":"Mahalingam","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2026062606020694500_bib20","doi-asserted-by":"crossref","first-page":"217496","DOI":"10.1016\/j.canlet.2025.217496","article-title":"REDD1 is a determinant of the sensitivity of renal cell carcinoma cells to autophagy inhibition that can be therapeutically exploited by targeting PIM activity","volume":"613","author":"Carew","year":"2025","journal-title":"Cancer Lett"},{"key":"2026062606020694500_bib21","doi-asserted-by":"crossref","first-page":"e1006752","DOI":"10.1371\/journal.pcbi.1006752","article-title":"Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer","volume":"15","author":"Malyutina","year":"2019","journal-title":"PLoS Comput Biol"},{"key":"2026062606020694500_bib22","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/bloodadvances.2018028480","article-title":"Complex karyotype AML displays G2\/M signature and hypersensitivity to PLK1 inhibition","volume":"3","author":"Moison","year":"2019","journal-title":"Blood Adv"},{"key":"2026062606020694500_bib23","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2767-9764.CRC-24-0260","article-title":"PLK1 inhibition induces synthetic lethality in fanconi anemia pathway-deficient acute myeloid leukemia","volume":"5","author":"Sheth","year":"2025","journal-title":"Cancer Res Commun"},{"key":"2026062606020694500_bib24","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.4161\/auto.29231","article-title":"Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors","volume":"10","author":"Mahalingam","year":"2014","journal-title":"Autophagy"},{"key":"2026062606020694500_bib25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/2767-9764.CRC-22-0340","article-title":"Targeting NEDDylation is a novel strategy to attenuate cisplatin-induced nephrotoxicity","volume":"3","author":"Jones","year":"2023","journal-title":"Cancer Res Commun"},{"key":"2026062606020694500_bib26","doi-asserted-by":"crossref","first-page":"e0343422","DOI":"10.1371\/journal.pone.0343422","article-title":"Robust predictors for drug response of patients with acute myeloid leukemia","volume":"21","author":"Tercan","year":"2026","journal-title":"PLoS One"},{"key":"2026062606020694500_bib27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1158\/1078-0432.CCR-14-1960","article-title":"The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine","volume":"21","author":"Nawrocki","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026062606020694500_bib28","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1182\/blood-2009-11-254862","article-title":"Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia","volume":"115","author":"Swords","year":"2010","journal-title":"Blood"},{"key":"2026062606020694500_bib29","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/leu.2015.250","article-title":"Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine","volume":"30","author":"Visconte","year":"2016","journal-title":"Leukemia"},{"key":"2026062606020694500_bib30","doi-asserted-by":"crossref","first-page":"eabg1168","DOI":"10.1126\/scitranslmed.abg1168","article-title":"Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor","volume":"13","author":"Roux","year":"2021","journal-title":"Sci Transl Med"},{"key":"2026062606020694500_bib31","doi-asserted-by":"crossref","first-page":"101645","DOI":"10.1016\/j.xcrm.2024.101645","article-title":"Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling","volume":"5","author":"Chen","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026062606020694500_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/leu.2014.222","article-title":"Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy","volume":"29","author":"Gjertsen","year":"2015","journal-title":"Leukemia"},{"key":"2026062606020694500_bib33","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bbrc.2006.12.206","article-title":"Targeted deletion of p97 (VCP\/CDC48) in mouse results in early embryonic lethality","volume":"354","author":"M\u00fcller","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"2026062606020694500_bib34","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.3390\/cancers14122949","article-title":"Multiple components of protein homeostasis pathway can be targeted to produce drug synergies with VCP inhibitors in ovarian cancer","volume":"14","author":"Bastola","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026062606020694500_bib35","doi-asserted-by":"crossref","first-page":"17065","DOI":"10.1038\/cddiscovery.2017.65","article-title":"Specific mutations in the D1-D2 linker region of VCP\/p97 enhance ATPase activity and confer resistance to VCP inhibitors","volume":"3","author":"Bastola","year":"2017","journal-title":"Cell Death Discov"},{"key":"2026062606020694500_bib36","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41419-021-03555-5","article-title":"p97\/VCP is highly expressed in the stem-like cells of breast cancer and controls cancer stemness partly through the unfolded protein response","volume":"12","author":"Li","year":"2021","journal-title":"Cell Death Dis"},{"key":"2026062606020694500_bib37","doi-asserted-by":"crossref","first-page":"e58424","DOI":"10.1371\/journal.pone.0058424","article-title":"The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia","volume":"8","author":"Casolaro","year":"2013","journal-title":"PLoS One"},{"key":"2026062606020694500_bib38","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12185-020-02994-8","article-title":"Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia","volume":"113","author":"Cortes","year":"2021","journal-title":"Int J Hematol"},{"key":"2026062606020694500_bib39","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1007\/s00277-023-05442-9","article-title":"Spliceosome mutations are associated with clinical response in a phase 1b\/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia","volume":"102","author":"Croucher","year":"2023","journal-title":"Ann Hematol"},{"key":"2026062606020694500_bib40","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-20-2586","article-title":"A phase Ib study of onvansertib, a novel oral PLK1 inhibitor, in combination therapy for patients with relapsed or refractory acute myeloid leukemia","volume":"26","author":"Zeidan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026062606020694500_bib41","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-020-00956-5","article-title":"Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation","volume":"13","author":"Topatana","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2026062606020694500_bib42","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/17474086.2025.2487605","article-title":"Oral decitabine in acute myeloid leukemia: assessing efficacy, safety, and future implications for older patients","volume":"18","author":"Niscola","year":"2025","journal-title":"Expert Rev Hematol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0035\/3801779\/crc-26-0035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/6\/1509\/3807215\/crc-26-0035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/6\/1509\/3807215\/crc-26-0035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:02:19Z","timestamp":1782468139000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/6\/1509\/786204\/p97-Inhibition-Synergistically-Enhances"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0035","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32802476","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32802497","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32802500","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32802488","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32802494","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32802482","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32802473","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32802485","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32802470","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32802491","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32802506","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32802479","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32802503","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8560202","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}